Aimmune's peanut allergy drug meets main goal, shares surge

(Reuters) – U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

Source: Reuters Medical News